FUL

Business Context and Reporting Period

Company: H.B. Fuller Company (H.B. Fuller)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three months ended February 28, 2026

Business Overview: H.B. Fuller is a global manufacturer of functional coatings, adhesives, sealants, and elastomers. The company operates through three reportable segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Building Adhesive Solutions.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenue decreased 2.3% year-over-year. This was driven by a 7.2% decrease in sales volume, partially offset by a 3.6% positive currency impact, 0.7% from acquisitions, and 0.6% from pricing.
• Margin Expansion: Gross profit margin improved by 180 basis points to 30.6%, attributed to higher product pricing, lower raw material costs, and the impact of acquisitions.
• Profitability Surge: Net income increased 59.1% to $21.0 million, and Adjusted EBITDA rose 3.8% to $118.7 million, despite lower revenue, due to margin improvements and cost management.
• Segment Performance:
  • Hygiene, Health and Consumable Adhesives: Revenue down 5.9%; Adjusted EBITDA up 2.3%.
  • Engineering Adhesives: Revenue up 2.4%; Adjusted EBITDA up 9.0%.
  • Building Adhesive Solutions: Revenue down 1.0%; Adjusted EBITDA down 0.9%.
• Cash Flow Improvement: Operating cash flow usage narrowed significantly from $(52.9) million in Q1 2025 to $(4.0) million in Q1 2026, primarily due to better collection of trade receivables ($39.6 million source vs. $13.9 million prior year).

Guidance, Outlook, and Risks

• Restructuring Initiatives:
  • 2023 Plans: Expected total pre-tax costs of $85.0–$90.0 million. As of Feb 28, 2026, $83.2 million has been incurred. Remaining payments expected in fiscal 2026.
  • New 2026 Actions: Approved new footprint optimization actions with expected pre-tax costs of $10.2–$12.2 million. Implementation expected through fiscal 2028.
• Acquisitions: Completed acquisition of ND Industries Turkey (Nov 2025) and previously GEM/Medifill (Jan 2025) and ND Industries Taiwan (Feb 2025). These are expected to drive growth in EIMEA and Greater Asia.
• Liquidity and Debt: Total debt to total capital ratio is 50.1%. The company is in compliance with all credit agreement covenants (Leverage ratio 2.3x; Interest coverage 5.0x).
• Legal Contingencies:
  • Asbestos Litigation: Settled 2 claims for $258k in Q1 2026. Company maintains insurance and indemnification agreements; does not expect material adverse effect.
  • Rouse et al. v. H.B. Fuller: Accrued $34.8 million (pre-tax) for a potential settlement regarding grout defects from a divested business. Company expects substantial reimbursement from insurers.
• Share Repurchases: No shares repurchased under the $300 million program in Q1 2026. Approximately $211 million remains available under the program.

Investor Verification Checklist

• Volume vs. Pricing: Verify the sustainability of the 0.6% pricing increase given the 7.2% volume decline across all segments.
• Working Capital Trends: Monitor the increase in Inventory Days on Hand (90 days vs. 79 days prior year) and its impact on future cash flow.
• Restructuring Execution: Track the timing and cash impact of the new $10.2–$12.2 million restructuring plan approved in Q1 2026.
• Legal Accruals: Confirm the status of the $34.8 million accrual for the Rouse litigation and the progress of insurance reimbursement claims.
• Acquisition Integration: Assess the contribution of recent acquisitions (ND Industries, GEM, Medifill) to the 0.7% revenue growth and margin expansion.